



Article

# Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms

Max Bermes <sup>1,2</sup>, Maria Jimena Rodriguez <sup>1,2</sup>, Marcelo Augusto Szymanski de Toledo <sup>1,2</sup> , Sabrina Ernst <sup>3</sup>, Gerhard Müller-Newen <sup>4</sup>, Tim Henrik Brümmendorf <sup>1,2</sup> , Nicolas Chatain <sup>1,2</sup> , Steffen Koschmieder <sup>1,2,\*</sup> and Julian Baumeister <sup>1,2,†</sup>

<sup>1</sup> Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; max.bermes@rwth-aachen.de (M.B.); mrodriguez@ukaachen.de (M.J.R.); mszymanskide@ukaachen.de (M.A.S.d.T.); tbruemmendorf@ukaachen.de (T.H.B.); nchatain@ukaachen.de (N.C.); jbaumeister@ukaachen.de (J.B.)

<sup>2</sup> Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany

<sup>3</sup> Confocal Microscopy Facility, Interdisciplinary Center for Clinical Research IZKF, RWTH Aachen University, 52074 Aachen, Germany; sabernst@ukaachen.de

<sup>4</sup> Department of Biochemistry, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; gmueller-newen@ukaachen.de

\* Correspondence: skoschmieder@ukaachen.de; Tel.: +49-241-8036102

† These authors contributed equally to this work.

**Abstract:** Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., *BRCA1*). We investigated the therapeutic potential of targeting *BRCA1* haploinsufficiency alongside the *JAK2V617F* driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha ( $\text{IFN}\alpha$ ) in CRISPR/Cas9-engineered *Brca1*<sup>+/-</sup> *Jak2V617F*-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by  $\gamma\text{H2AX}$  analysis through Western blot ( $p = 0.024$ ), flow cytometry ( $p = 0.013$ ), and confocal microscopy ( $p = 0.071$ ). RAD51 foci formation was impaired in *Brca1*<sup>+/-</sup> cells compared to *Brca1*<sup>+/+</sup> cells, indicating impaired homologous recombination repair due to *Brca1* haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in *Brca1*<sup>+/-</sup> cells compared to *Brca1*<sup>+/+</sup> cells. These effects were further potentiated by  $\text{IFN}\alpha$ . Olaparib induced interferon-stimulated genes and increased endogenous production of  $\text{IFN}\alpha$  in *Brca1*<sup>+/-</sup> cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and  $\text{IFN}\alpha$  presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline *BRCA1* mutations and the *JAK2V617F* MPN driver mutation.

**Keywords:** myeloproliferative neoplasms; MPN; *BRCA1*; haploinsufficiency; olaparib; interferon-alpha;  $\text{IFN}\alpha$ ; DNA repair; homologous recombination repair; synthetic lethality



**Citation:** Bermes, M.; Rodriguez, M.J.; de Toledo, M.A.S.; Ernst, S.; Müller-Newen, G.; Brümmendorf, T.H.; Chatain, N.; Koschmieder, S.; Baumeister, J. Exploiting Synthetic Lethality between Germline *BRCA1* Haploinsufficiency and PARP Inhibition in *JAK2V617F*-Positive Myeloproliferative Neoplasms. *Int. J. Mol. Sci.* **2023**, *24*, 17560. <https://doi.org/10.3390/ijms242417560>

Academic Editor: Elena Levantini

Received: 18 October 2023

Revised: 4 December 2023

Accepted: 10 December 2023

Published: 16 December 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Myeloproliferative neoplasms (MPN) are a rare type of blood cancer and a disorder of excess progenitor cell production induced by clonal hematopoietic stem cells (HSCs). Among the group of the *BCR-ABL1*-negative MPN, the three most frequent subtypes are essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). With the exception of a minority of triple-negative patients, these disease entities are typically induced by one of three classical driver mutations in the genes encoding the tyrosine kinase Janus kinase 2 (*JAK2*), the chaperone calreticulin (*CALR*), or the thrombopoietin receptor *MPL*, the most frequent being the *JAK2V617F* mutation [1]. Although MPN patients

generally exhibit a more favorable prognosis compared to other hematologic malignancies, they face an increased risk of severe thrombotic and hemorrhagic events, leading to increased mortality [2].

Additionally, secondary myelofibrosis or transformation into acute myeloid leukemia (AML) can occur, significantly worsening the prognosis [3]. Hence, there is an urgent need for effective treatment strategies to enhance patients' quality of life and improve complication-free survival. Currently, allogeneic HSC transplantation remains the only curative therapeutic option. However, due to its high morbidity and mortality, only few patients are eligible for this intervention [4].

MPN mostly occur sporadically, but in 7.6% of the cases, MPN are associated with a familial incidence [5]. In these familial MPN, affected family members may present with different MPN subtypes or driver mutations, implying a shared genetic predisposition for acquiring these driver mutations [6]. Utilizing whole-exome sequencing, we could demonstrate that four out of five families with familial MPN presented with germline mutations in genes involved in DNA double-strand break (DSB) repair-associated genes (i.e., *BRCA1*, *BRCA2*, *ATM*, and *CHEK2*), suggesting that these germline mutations might increase the risk of acquiring a somatic MPN driver mutation [7].

*BRCA1* or *BRCA2* (*BRCA1/2*)-mutated cancer cells are effectively targeted by poly ADP ribose polymerase (PARP) inhibitors, leveraging the principle of synthetic lethality [8,9]. This concept was first described in 1922 by Calvin Bridges, who observed that the simultaneous loss of two distinct genes was lethal for flies, while the loss of one alone was not [10]. In the context of *BRCA1/2*-mutated cancer cells, PARP plays a pivotal role in DNA single-strand break (SSB) repair. Inhibiting PARP impedes the repair of DNA SSBs, causing them to progress into more severe DSBs. In *BRCA1/2*-mutated cells, characterized by defective homologous recombination repair (HRR), PARP inhibition induces a substantial load of DSBs that surpass their repair capacity. This results in the accumulation of DNA damage, ultimately triggering apoptosis through the phenomenon of synthetic lethality existing between *BRCA1/2* mutations and PARP inhibition.

This concept is already exploited clinically in familial breast and ovarian cancer, where patients often harbor a heterozygous *BRCA1/2* germline mutation and develop cancer after a somatic loss of the second allele. These cancer cells can be targeted specifically with PARP inhibitors, while non-malignant cells, which have retained one functional allele, remain unaffected [11]. While it is widely accepted that the loss of the second allele is a prerequisite for carcinogenicity in breast cancer and ovarian cancer, *BRCA1* haploinsufficient cells show functional deficits under challenging conditions, such as replicative stress [12,13]. In the context of MPN, driver mutations, such as *JAK2V617F*, induce replicative stress and genetic instability [14–17]. Building upon this knowledge, we postulated that PARP inhibition induces synthetic lethality, specifically in *BRCA1* haploinsufficient *JAK2V617F*-positive cells.


Recent research utilizing an ataxia telangiectasia mutated (*ATM*) model, with *ATM* serving as the apex kinase regulating *BRCA1*, has unveiled that DNA damage induced by *ATM* loss-of-function mutations primes the type I interferon system via the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway [18]. Interferon-alpha (*IFN* $\alpha$ ) is a widely used therapeutic option in the treatment of MPN and is recognized for its ability to selectively target malignant stem cells, evoke long-lasting deep molecular remissions, and induce DNA stress [19–21]. With this understanding, we hypothesized that MPN cells harboring heterozygous *BRCA1* mutations exhibit heightened responsiveness to *IFN* $\alpha$  treatment and that *IFN* $\alpha$  could potentially enhance the sensitivity of MPN cells with DSB repair gene haploinsufficiency to PARP inhibitors.

## 2. Results

### 2.1. DNA DSBs Are Elevated in *Brca1*<sup>+/-</sup> *Jak2V617F* Cells and Further Amplified by Olaparib

The first aim of this study was to assess whether 32D *Jak2V617F Brca1*<sup>+/-</sup> cells exhibited elevated numbers of DNA DSBs compared to their *Jak2V617F Brca1*<sup>+/+</sup> counterparts.

We also investigated whether olaparib, IFN $\alpha$ , or their combination induced more DSBs selectively in *Brca1*<sup>+/-</sup> cells. For this purpose, cells were treated with olaparib and/or IFN $\alpha$  for 24 h and analyzed for the frequency of  $\gamma$ H2AX-positive cells by flow cytometry (Figure 1A). While olaparib alone exhibited a stronger impact on inducing DSBs than IFN $\alpha$ , the combined treatment showed the most pronounced impact. When compared to *Brca1*<sup>+/+</sup> control cells, percentages of *Jak2*<sup>V617F</sup> *Brca1*<sup>+/-</sup> cells positive for  $\gamma$ H2AX were significantly higher when treated with olaparib and the combination of olaparib and IFN $\alpha$ .



**Figure 1.** Enhanced double-strand break induction by olaparib in *Brca1*<sup>+/-</sup> *Jak2*<sup>V617F</sup> cells. (A) *Jak2*<sup>V617F</sup> *Brca1*<sup>+/+</sup> and *Brca1*<sup>+/-</sup> cells were treated with olaparib (ola, 10  $\mu$ M), interferon-alpha (IFN $\alpha$ , 10,000 U/mL), or DMSO for 24 h. As a negative control, cells were treated with the ATM inhibitor Ku55933 (Ku, 10  $\mu$ M) and as a positive control, cells were treated with the topoisomerase II inhibitor etoposide (eto, 10  $\mu$ M). After treatment, the cells were stained with a phospho-histone H2A.X (Ser139) monoclonal antibody and FxCycle™ Violet stain and then analyzed by flow cytometry ( $n = 4$  of two clones respectively, exemplary flow cytometry plots see Figure S1). (B) Protein levels of

$\gamma$ H2AX and protein PARylation were analyzed in *Jak2V617F Brca1<sup>+/+</sup>* and *Brca1<sup>+/-</sup>* cells after incubation for 4 h with olaparib (10  $\mu$ M), IFN $\alpha$  (10,000 U/mL), and DMSO by Western blot (WB) using GAPDH as a loading control. (C)  $\gamma$ H2AX and (D) PAR densitometric analyses from four independent WB experiments (relative to GAPDH as loading control and relative to *Brca1<sup>+/+</sup>* DMSO,  $n = 4$  with two clones each). Data are presented as mean  $\pm$  SD and significances defined as: \*  $p < 0.05$  and \*\*  $p < 0.01$ , ns means no significance.


To confirm and complement the findings obtained from the flow cytometry analysis, we conducted Western blot experiments using *Jak2V617F Brca1<sup>+/+</sup>* and *Brca1<sup>+/-</sup>* cells after in vitro treatment with olaparib and/or IFN $\alpha$  for 4 h (Figure 1B–D). In *Brca1<sup>+/-</sup>* cells, we observed a significant increase in  $\gamma$ H2AX levels following treatment with DMSO, olaparib and the olaparib/IFN $\alpha$  combination, in comparison to *Brca1<sup>+/+</sup>* cells (Figure 1B,C). Additionally, basal levels of protein poly ADP-ribosylation (PARylation), a post-translational modification at DNA lesions catalyzed by PARP, were significantly higher in the *Brca1<sup>+/-</sup>* cells compared to the *Brca1<sup>+/+</sup>* cells (Figure 1B,D). As expected, PARylation was effectively inhibited by olaparib treatment.

## 2.2. Impaired HRR Mechanism and Suppressed Proliferation and Viability in *Brca1<sup>+/-</sup> Jak2V617F* Cells upon Treatment with Olaparib and IFN $\alpha$


To investigate the impact of *Brca1* haploinsufficiency on HRR within *Jak2V617F* cells, we analyzed the formation of  $\gamma$ H2AX and RAD51 foci using immunofluorescence and confocal microscopy, following 24 h treatment with olaparib or DMSO. RAD51 foci are crucial indicators of HRR functionality and are commonly examined to assess impairment of this repair pathway [22]. As expected, olaparib treatment prominently triggered the formation of  $\gamma$ H2AX foci (Figure 2A). Although not reaching statistical significance, there was a numerical enhancement in the induction of  $\gamma$ H2AX foci in *Brca1<sup>+/-</sup>* cells in comparison to *Brca1<sup>+/+</sup>* cells (Figure 2B). When analyzing RAD51 foci numbers, we observed an induction by olaparib, which was significantly higher in *Brca1<sup>+/+</sup>* cells (Figure 2C). Olaparib-treated *Brca1<sup>+/-</sup>* cells displayed an increased number of  $\gamma$ H2AX foci without a corresponding RAD51 focus compared with *Brca1<sup>+/-</sup>* cells ( $p = 0.1378$ ; Figure S1K).

Having demonstrated the induction of DSBs by both olaparib and IFN $\alpha$  in *Jak2V617F* cells, with a notably higher effect in *Brca1<sup>+/-</sup>* cells compared to *Brca1<sup>+/+</sup>* cells, we examined the effects of olaparib and IFN $\alpha$  on cell proliferation and cell viability. Our findings revealed that olaparib, IFN $\alpha$ , and their combination significantly reduced cell viability and cell proliferation in *Brca1<sup>+/-</sup> Jak2V617F* cells compared to *Brca1<sup>+/+</sup> Jak2V617F* cells (Figures 3A and S2A). Most importantly, and in line with the findings of our preceding experiments, proliferation, and viability were considerably more impaired in *Brca1<sup>+/-</sup>* cells than in *Brca1<sup>+/+</sup>* cells when subjected to olaparib, IFN $\alpha$ , or the combination.

Thereafter, we studied the effect of olaparib and IFN $\alpha$  on *Jak2V617F Brca1<sup>+/-</sup>* and *Brca1<sup>+/+</sup>* cells using MTT assays as an indicator of cell viability, proliferation, and cytotoxicity (Figures 3B–D and S2B–D). These assays revealed that the reduction in metabolic activity was significantly more pronounced in *Jak2V617F Brca1<sup>+/-</sup>* cells than in *Jak2V617F Brca1<sup>+/+</sup>* cells when treated with olaparib (Figures 3B and S2C,D), IFN $\alpha$  (Figures 3C and S2B,C), or the combination of both drugs (Figure 3D). We also analyzed the effect of olaparib and IFN $\alpha$  on the metabolic activity of 32D *Jak2* wildtype (WT) cells. Interestingly, olaparib and IFN $\alpha$  exhibited a weaker impact on the metabolic activity of *Jak2WT* cells, with olaparib still demonstrating a stronger effect on *Brca1<sup>+/-</sup>* cells than on *Brca1<sup>+/+</sup>* cells (Figure S3). However, for IFN $\alpha$ , no difference between *Brca1<sup>+/-</sup>* and *Brca1<sup>+/+</sup>* cells was observed. Moreover, by comparing the mean relative absorbances from the MTT assays with *Jak2WT* cells to those with *Jak2V617F* cells (Table S1), we found that both olaparib and IFN $\alpha$  led to a more pronounced impairment of metabolic activity in *Jak2V617F* than in *Jak2WT* cells. Moreover, olaparib treatment had a stronger impact on *Jak2V617F* cells compared to *Jak2WT* cells, which was not observed for IFN $\alpha$  treatment.



**Figure 2.** Impaired homologous recombination repair mechanism in olaparib-treated *Jak2V617F Brca1<sup>+/+</sup>* cells. **(A)** *Jak2V617F Brca1<sup>+/+</sup>* and *Brca1<sup>+/-</sup>* cells have been treated for 24 h with DMSO or olaparib (10  $\mu$ M), stained with anti-RAD51 and anti- $\gamma$ H2AX antibodies, incubated with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 and counterstained with Hoechst 33342. Images were taken with a Zeiss LSM 710 confocal microscope using Zen software (scale bar = 10  $\mu$ m). **(B)** The percentage of cells with  $\geq 10$   $\gamma$ H2AX foci was scored of at least 200 cells per condition ( $n = 4$ ). **(C)** The percentage of cells with  $\geq 5$  RAD51 foci was scored at least 200 cells per condition ( $n = 4$ ). Data are presented as mean  $\pm$  SD and significances defined as: \*  $p < 0.05$ .



To investigate the potential of olaparib and IFN $\alpha$  to induce apoptosis in *Jak2V617F Brca1<sup>+/-</sup>* and *Brca1<sup>+/+</sup>* cells, we utilized Annexin V/7-AAD apoptosis assays (Figure 3E). IFN $\alpha$  induced apoptosis to a greater extent than olaparib, whereas the combination provoked the strongest response. By calculating the coefficient of drug interaction (CDI), we observed higher synergistic effects of olaparib and IFN $\alpha$  in *Brca1<sup>+/-</sup>* cells than in *Brca1<sup>+/+</sup>* cells in MTT (Figure S4A) and apoptosis (Figure S4B) assays.


To assess the impact of olaparib and IFN $\alpha$  on the cell cycle of *Jak2V617F Brca1<sup>+/+</sup>* and *Brca1<sup>+/-</sup>* cells, we analyzed the fraction of cells in G<sub>0</sub>/G<sub>1</sub> or G<sub>2</sub>/M phase with FxCycle Violet by flow cytometry after 24 h of treatment with olaparib, IFN $\alpha$ , or their combination. A pronounced cell cycle arrest in G<sub>0</sub>/G<sub>1</sub> was induced in *Brca1<sup>+/-</sup>* cells following single treatments of olaparib and IFN $\alpha$ , and this effect was notably enhanced by the combination treatment (Figure S5A). In contrast, the reduction in the fraction of *Brca1<sup>+/+</sup>* cells in G<sub>2</sub>/M phase was less pronounced. Additionally, we analyzed the expression of negative cell cycle regulators, specifically p16 (i.e., *CDKN2A* gene) and p21 (i.e., *CDKN1A* gene). p16, also known as cyclin-dependent kinase inhibitor 2A, inhibits the progression from the G<sub>1</sub> phase to the S phase, and p21, also called cyclin-dependent kinase inhibitor 1, is involved in inhibiting the progression through the G<sub>1</sub>, the S, and the G<sub>2</sub> phases. The upregulation of p16 and p21 was significantly more pronounced in *Brca1<sup>+/-</sup>* cells when treated with both olaparib and IFN $\alpha$ , corroborating the flow cytometric cell cycle analysis (Figure S5B).

In summary, the results affirm our hypothesis that *Jak2V617F Brca1<sup>+/-</sup>* cells exhibit a higher number of DSBs compared with *Brca1<sup>+/+</sup>* cells. Notably, we found that this susceptibility to DSBs is specifically heightened in *Jak2V617F Brca1<sup>+/-</sup>* cells through PARP inhibition. Furthermore, olaparib and IFN $\alpha$  preferentially compromised the metabolic activity, proliferation, viability, and cell cycle progression of *Jak2V617F Brca1<sup>+/-</sup>* cells. These findings underscore the elevated sensitivity of *Brca1<sup>+/-</sup>* cells to these therapeutic interventions.

### 2.3. Olaparib Induces IFN $\alpha$ Signaling via Activation of the cGAS-STING Pathway Specifically in *Brca1<sup>+/-</sup> Jak2V617F* Cells


Intriguingly, recent evidence has suggested a link between DNA damage and the activation of the cGAS-STING pathway, which is one major pathway responsible for driving the production of IFN $\alpha$  in response to cytosolic microbial and self-DNA [23]. This pathway is part of the innate immune system and detects cytosolic microbial DNA but can also be activated by an accumulation of DNA damage, leading to the release of DNA into the cytoplasm and subsequent activation of the cGAS-STING pathway resulting in increased production of IFN $\alpha$  [18]. Therefore, we postulated that (a) the cGAS-STING pathway is constitutively active in *Jak2V617F Brca1<sup>+/-</sup>* cells and further augmented by olaparib treatment and (b) that the activated STING-pathway results in an elevated production of IFN $\alpha$  (Figure 4).

To test the hypothesis that the STING pathway is activated by cytoplasmic DNA as a result of increased DSBs in *Jak2V617F Brca1<sup>+/-</sup>* cells, we analyzed transcriptional levels of *Sting1* and several interferon-responsive genes (*Stat1*, *Irf7*, *Mx1*, *Oas1a*, and *Isg15*) in *Jak2V617F Brca1<sup>+/-</sup>* and *Jak2V617F Brca1<sup>+/+</sup>* cells after treatment with olaparib, IFN $\alpha$ , or the combination (Figure 5). As expected, we observed an upregulation of all interferon-responsive genes after treatment with IFN $\alpha$ , and mRNA levels of *Sting1* were not elevated in *Brca1<sup>+/-</sup>* cells upon treatments but even downregulated in the basal condition. However, interestingly, olaparib treatment induced the expression of *Irf7*, *Mx1*, *Oas1a*, and *Isg15* in *Jak2V617F Brca1<sup>+/-</sup>* cells compared to *Jak2V617F Brca1<sup>+/+</sup>* cells. Moreover, the basal expression of *Isg15* and *Mx1* was elevated in *Brca1<sup>+/-</sup>* compared to *Brca1<sup>+/+</sup>* cells, and when treated with both olaparib and IFN $\alpha$ , *Stat1*, *Oas1a*, and *Isg15* exhibited significant upregulation in *Brca1<sup>+/-</sup>* cells.




**Figure 4.** Hypothesis: PARP inhibition activates the cGAS-STING pathway in *Jak2V617F Brca1<sup>+/-</sup>* cells. (1) The *Jak2V617F* mutation leads to the formation of reactive oxygen species and thereby causes DNA stress, resulting in an increased number of single- and double-strand breaks (SSBs/DSBs). (2) PARP inhibition suppresses the repair of SSBs, resulting in the formation of double-strand breaks (DSBs) that also cannot be repaired sufficiently due to the *Brca1* haploinsufficiency. (3) The accumulation of DSBs results in the translocation of DNA fragments into the cytoplasm. (4) cGAS recognizes cytosolic DNA and, upon detection of cytosolic DNA, synthesizes cGAMP. (5) cGAMP is detected by STING and, together with TBK1, phosphorylates and activates the transcription factors NF-κB and IRF3. (6) NF-κB and IRF3 translocate into the nucleus and induce the production of proinflammatory cytokines (e.g., TNF, IL-6, type I interferons). (7) Those cytokines are secreted into the interstitium where they bind to the membrane receptors of the original and the surrounding cells and hence induce a proinflammatory state. Created with [BioRender.com](https://BioRender.com) (accessed on 17 October 2023).

To confirm that the induction of the interferon-responsive genes was indeed a result of cGAS-STING pathway activation, we conducted a secretion assay, as this pathway is also known to induce heightened expression and secretion of IFN $\alpha$ . Supernatant harvested from olaparib- or DMSO-treated *Jak2V617F Brca1<sup>+/-</sup>* and *Brca1<sup>+/+</sup>* cells, was added to freshly seeded *Jak2V617F Brca1<sup>+/+</sup>* cells. The expression of interferon-responsive genes was then assessed by RT-qPCR to determine whether olaparib-treated cells had secreted IFN $\alpha$  (Figure 6A). We found that, indeed, basal levels of *Oas1a* and *Isg15* were upregulated in those cells that have received supernatant from *Jak2V617F Brca1<sup>+/-</sup>* cells compared to *Jak2V617F Brca1<sup>+/+</sup>* cells. This effect was further enhanced by olaparib treatment. Importantly, this effect was not observed when the cells were preincubated with an IFN $\alpha$ R1 blocking antibody before adding the supernatant, confirming that *Brca1* haploinsufficiency in *Jak2V617F Brca1<sup>+/-</sup>* cells stimulates an increased production of IFN $\alpha$ .



**Figure 5.** Induction of cGAS-STING pathway target genes by olaparib in *Brca1*<sup>+/-</sup> *Jak2*<sup>V617F</sup> cells. mRNA levels of *Sting1*, *Stat1*, *Irf7*, *Mx1*, *Oas1*, and *Isg15* in *Jak2*<sup>V617F</sup> *Brca1*<sup>+/+</sup> and *Brca1*<sup>+/-</sup> cells treated for 24 h with olaparib (ola, 10 μM), interferon-alpha (IFNα, 10,000 U/mL), the combination, or DMSO (*n* = 3 with two clones each). Data are presented as mean ± SD and significances defined as: \* *p* < 0.05, \*\* *p* < 0.01, and \*\*\*\* *p* < 0.0001, ns means no significance.



**Figure 6.** cGAS-STING pathway activation augments the production of IFN $\alpha$  in *Brca1*<sup>+/-</sup> *Jak2V617F* cells. (A) *Jak2V617F Brca1*<sup>+/-</sup> and *Brca1*<sup>+/+</sup> cells were first treated for 24 h with olaparib (10  $\mu$ M) and then cultivated in new medium for 4 h. The supernatant (SN) was added to new *Brca1*<sup>+/+</sup> cells for 24 h, and transcriptional levels of the interferon-stimulated genes (ISGs) *Mx1*, *Oas1a*, and *Isg15* were analyzed by RT-qPCR. As a negative control, the cells were incubated with an IFN $\alpha$ R1 blocking antibody ( $n = 3$  with two clones each). (B) *Jak2V617F Brca1*<sup>+/-</sup> and *Brca1*<sup>+/+</sup> cells were treated with olaparib (ola, 10  $\mu$ M) and the STING inhibitor H-151 (0.75  $\mu$ M) for 24 h, and gene expression of *Mx1*, *Oas1a* and *Isg15* was analyzed by RT-qPCR ( $n = 4$  with two clones each). Statistical analysis was performed using one-way ANOVA. Data are presented as mean  $\pm$  SD and significances defined as: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , and \*\*\*\*  $p < 0.0001$ , ns means no significance.

Finally, to verify that the upregulation of interferon-responsive genes and the increased production of IFN $\alpha$  are indeed mediated through the cGAS-STING pathway, we treated *Jak2V617F Brca1*<sup>+/-</sup> and *Brca1*<sup>+/+</sup> cells with olaparib and the STING inhibitor H-151. Subsequently, we analyzed the expression of three interferon-stimulated genes (ISGs): *Mx1*, *Oas1a*, and *Isg15* (Figure 6B). Intriguingly, we observed that the increased ISG expression levels in *Brca1*<sup>+/-</sup> cells after treatment with olaparib were antagonized by STING inhibition,

except for *Oas1a*. These findings indicate that DNA damage induced by PARP inhibition leads to an activation of the cGAS-STING pathway with subsequent increased production of IFN $\alpha$  in *Jak2V617F*-positive *Brca1* haploinsufficient cells. This unique interplay potentially renders these cells more susceptible to IFN $\alpha$  and other MPN-directed treatments.

### 3. Discussion

Loss-of-function mutations of DNA repair-associated genes play a role in many types of cancer, but their potential significance in MPN has only recently been suggested by a whole-exome sequencing study of our group, in which heterozygous germline mutations in DSB repair genes have been identified in four out of five families with familial MPN [7]. Moreover, even in patients with sporadic MPN, the natural incidence of germline mutations in DSB repair genes would be expected to be at least 0.1–0.5% since this is the combined incidence of *BRCA1* and *BRCA2* mutations in the general population [24]. As it is already known that cancers harboring germline mutations in DSB repair-associated genes are susceptible to PARP inhibition, it is tempting to consider whether this principle could also be translated to patients with familial or sporadic MPN. Currently, no clear recommendations on how to manage these MPN patients are available.

In this study, we demonstrated that heterozygous *Brca1* mutations in 32D *Jak2V617F* cells result in impaired HRR, suggesting a potential therapeutic vulnerability that could be exploited by PARP inhibitors. As previously reported, *JAK2V617F* induces DNA damage [14,15], and our findings suggest that *Jak2V617F*-positive cells harboring an additional heterozygous *Brca1* mutation experience even greater DNA damage, surpassing the capacity of the defective DSB repair machinery. This effect is notably amplified by olaparib, with significantly elevated  $\gamma$ H2AX levels as demonstrated by Western blot and flow cytometry, further supported by close-to-significant immunofluorescence analyses ( $p = 0.07$ ). Based on these findings, we propose that PARP inhibition could offer a promising therapeutic strategy for familial MPN patients carrying DSB repair-associated germline mutations by exploiting synthetic lethality. Furthermore, we observed an activation of the STING pathway in olaparib-treated *Brca1*<sup>+/-</sup> *Jak2V617F* cells, leading to an increased secretion of IFN $\alpha$ . This cytokine, which has emerged as a standard treatment in MPN, exhibited enhanced efficacy in *Brca1*<sup>+/-</sup> *Jak2V617F* cells compared to *Brca1*<sup>+/+</sup> cells. While IFN $\alpha$  is capable of inducing long-lasting deep molecular remission and promoting the cycling of dormant stem cells [25,26], the combination of IFN $\alpha$  with olaparib presents a potential synergistic drug combination worthy of further investigation.

IFN $\alpha$  selectively induces cycling of the *JAK2V617F* HSC, leading to cell cycle stress-associated genomic instability and increased susceptibility towards PARP inhibition, particularly in cells with defective DNA repair mechanisms. To our knowledge, this therapeutic approach of combining PARP inhibitors with IFN $\alpha$  has not been investigated yet and holds potential for application in non-familial MPN patients as well, as *BRCA1* is epigenetically inactivated in 40% of all MPN samples analyzed [22], and alterations in DNA repair genes are a frequent feature in MPN patients [27]. This suggests that effective treatment options targeting defective DNA repair mechanisms might extend beyond familial MPN cases to encompass a larger cohort of MPN patients who could benefit from this targeted therapeutic approach. Supporting this notion, the effectiveness of PARP inhibitors in MPN with no detected DSB repair-associated gene mutation has already been demonstrated [28].

The cGAS-STING pathway has been recognized as an activator of the antitumor immune response [29], and in triple-negative breast cancer, the efficacy of olaparib depends on the activation of the cGAS-STING pathway, which recruits CD8<sup>+</sup> T cells into the tumor microenvironment, thereby triggering an antitumor immune response [30]. Our findings indicate that olaparib induces an upregulation of the cGAS-STING pathway in *Brca1*<sup>+/-</sup> cells, leading to an increase in intrinsic IFN $\alpha$  production.

Our study on murine *Jak2V617F*-positive 32D cells indicates the potential relevance of *Brca1* haploinsufficiency to human MPN disease. Given the rarity of MPN and the low prevalence of *BRCA1* mutations in the general population, identifying MPN patients

harboring *BRCA1* mutations is challenging. To address this, we are actively conducting an extensive screening on patients with familial MPN. Subsequently, we plan to validate our mechanistic findings in further studies, utilizing primary MPN patient samples harboring *BRCA1* mutations and haploinsufficient *Brca1* animal models to assess how the concept of synthetic lethality between *BRCA1* haploinsufficiency and PARP inhibition translates clinically into JAK2V617F-driven MPN. Considering that *BRCA1* mutations in patients with familial MPN extend beyond the bone marrow, data from triple-negative breast and ovarian cancer patients harboring heterozygous germline *BRCA1* mutations who have undergone olaparib treatment might aid in estimating treatment-associated side effects on *BRCA1*-haploinsufficient non-cancerous cells. Nevertheless, our MTT assays have already demonstrated that both olaparib and the combination with IFN $\alpha$  exert a more pronounced effect on *Brca1*<sup>+/-</sup> cells with an additional *Jak2V617F* driver mutation when compared to *Brca1*<sup>+/-</sup> *Jak2WT* cells. Although PARP inhibitors are already approved for the treatment of other cancers and their efficacy and safety have been assessed in clinical trials [31,32], in vivo studies are required to assess the efficacy and safety of PARP inhibitors, both alone and in combination with IFN $\alpha$ , for the treatment in MPN. Additionally, considering that PARP inhibitors may impair DNA damage repair and pose a carcinogenic risk for homologous recombination proficient cells [33], further studies are required to estimate the risk of developing secondary cancers. This is underlined by reports suggesting an increased risk of developing AML or myelodysplastic syndrome in breast or ovarian cancer patients treated with PARP inhibitors over extended periods [34]. In conclusion, our findings suggest the potential of combining olaparib and IFN $\alpha$  as a promising therapeutic strategy in MPN patients by exploiting the synthetic lethality between germline *BRCA1* mutations and the JAK2V617F MPN driver mutation.

#### 4. Materials and Methods

##### 4.1. Cell Lines

32D *Jak2V617F Brca1*<sup>+/-</sup> cells were generated by CRISPR/Cas9 using two guideRNAs targeting *Brca1* exon 10 (CD.Cas9.LFMV2350.AA (AGTCCAAAGGTGACAGCTAA) and CD.Cas9.LFMV2350.AB (GGTTAAGCGCGTGTCTCAAG) and Cas9 nuclease according to the manufacturer's protocol (IDT technologies, Coralville, IA, USA). Parental 32D cells (RRID:CVCL\_0118, DSMZ, Braunschweig, Germany) were retrovirally transduced with pMSCV-*Jak2V617F*-IRES-GFP. Clones were screened by Sanger sequencing (genomic DNA and mRNA) for frameshift mutations inducing premature stop codons in the same region as the human *BRCA1* c.2722G>T Glu908\* missense mutation that was identified in our whole-exome sequencing analysis in familial MPN [7]. Off-target analysis was performed as described in the Supplementary Materials and relevant off-target effects of the CRISPR/Cas9 process were ruled out. In all experiments, two different clones of each genotype were examined.

##### 4.2. Flow Cytometry Analysis of DSBs

We treated,  $2 \times 10^6$  cells in a concentration of  $1 \times 10^6$  cells/mL with either DMSO (Serva, Heidelberg, Germany) or olaparib (10  $\mu$ M) (Selleckchem, Cologne, Germany) and with H<sub>2</sub>O or IFN $\alpha$  (10,000 U/mL) in RPMI-1640 (PAN-Biotech, Aidenbach, Germany) medium with 10% fetal calf serum (FCS; PAN-Biotech), 5 ng/mL murine interleukin 3 (mIL-3, ImmunoTools, Friesoythe, Germany), and 1% penicillin/streptomycin (Gibco-Thermo Fisher Scientific, Waltham, MA, USA) for 24 h. The positive control was treated with etoposide (10  $\mu$ M) (Merck, Darmstadt, Germany) for 4 h, and the negative control was treated with the ATM inhibitor Ku55933 (10  $\mu$ M) (Selleckchem) for 4 h. Cells were fixed and permeabilized using the FIX and PERM Cell Fixation and Cell Permeabilization Kit (Thermo Fisher Scientific, Waltham, WA, USA) and stained with Phospho-Histone H2A.X ( $\gamma$ H2AX, Ser139) monoclonal antibody (CR55T33, PE) (eBioscience, Frankfurt am Main, Germany) and FxCycle Violet stain (Thermo Fisher Scientific). Cells were analyzed in a Gallios flow cytometer (Beckman Coulter, Pasadena, CA, USA) and analyzed with FlowJo

(LLC; v10, BD Life Sciences, Franklin Lakes, NJ, USA). A detailed protocol is provided in the Supplementary Materials.

#### 4.3. MTT Assay

We performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays as previously published but with  $1.5 \times 10^4$  cells per well instead of  $10^4$  cells in RPMI-1640 medium with 10% FCS, 5 ng/mL mIL-3 and 1% penicillin/streptomycin [35].

#### 4.4. SDS-PAGE and Western Blot

We treated  $2 \times 10^6$  cells in a concentration of  $1 \times 10^6$  cells/mL for 4 h with IFN $\alpha$  (10,000 U/mL), olaparib (10  $\mu$ M), or the combination in RPMI-1640 medium with 10% FCS, 5 ng/mL mIL-3, and 1% penicillin/streptomycin. Generation of lysates, SDS-PAGE, and Western blots were performed as previously published [36]. The used antibodies are listed in the Supplementary Materials (Table S2).

#### 4.5. Apoptosis Assay

We treated  $4 \times 10^5$  cells in a concentration of  $2 \times 10^5$  cells/mL for 48 h with olaparib (10  $\mu$ M) or IFN $\alpha$  (10,000 U/mL) in RPMI-1640 medium with 10% FCS, 5 ng/mL mIL-3, and 1% penicillin/streptomycin and then,  $1 \times 10^6$  cells were subjected to apoptosis assays, using the APC Annexin V Apoptosis Detection Kit (BioLegend, San Diego, CA, USA), with the samples being analyzed in triplicates with a Gallios flow cytometer (Beckman Coulter) and FlowJo (LLC; v10).

#### 4.6. Cell Proliferation Assay

The different cell clones were seeded in a concentration of  $2 \times 10^5$  cells/mL in RPMI-1640 medium with 10% FCS, 5 ng/mL mIL-3, and 1% penicillin/streptomycin and treated with the following drugs: IFN $\alpha$  (10,000 U/mL), olaparib (10  $\mu$ M), or the combination of IFN $\alpha$  and olaparib. Then, the cells were analyzed with a CASY-TTC cell analyzer (OMNI Life Science, Bremen, Germany) after 24 h, 48 h, and 72 h.

#### 4.7. RT-qPCR

Reverse transcriptase quantitative PCR (RT-qPCR) for the analysis of cDNA transcripts was performed as previously published (20). Primer sequences are given in the Supplementary Materials (Table S3).

#### 4.8. Confocal Microscopy Assay

We treated  $1 \times 10^5$  cells/mL with either olaparib (10  $\mu$ M) or DMSO in RPMI-1640 medium with 10% FCS, 5 ng/mL mIL-3, and 1% penicillin/streptomycin for 24 h. Then, the cells were harvested, washed with PBS 1X, and centrifuged using Cytospin 4 centrifuge (Thermo Fisher Scientific) at 650 rpm for 5 min. After fixation with 4% paraformaldehyde for 20 min, the cells were permeabilized with 0.5% Triton X-100 for 10 min, blocked with 5% BSA for 1 h, and incubated with primary antibodies ( $\gamma$ H2AX 1:500 Cell Signaling #9718, Danvers, MA, USA; RAD51 1:500 Invitrogen MA1-23271) at 4 °C overnight. Subsequently, the cells were washed and incubated with fluorochrome-conjugated secondary antibodies (anti-mouse Alexa Fluor 488 1:200 and anti-rabbit Alexa Fluor 594 1:200) for 1 h at room temperature, and nuclei were stained with Hoechst 33342 (Thermo Fisher Scientific). Images were captured with a Zeiss LSM 710 confocal microscope (Carl Zeiss GmbH, Jena, Germany) using ZEN black 2.3 SP1 software (version 14.0.27.201, Carl Zeiss GmbH). At least 200 cells in nine different areas of the sample were analyzed to quantify RAD51 and  $\gamma$ H2AX foci. For  $\gamma$ H2AX/RAD51 quantification, the percentage of cells with ten/five (respectively) or more foci per nucleus was scored.

#### 4.9. Secretion Assay

For every clone,  $5 \times 10^6$  cells were cultured in 5 mL RPMI-1640 medium with 10% FCS, 1% penicillin/streptomycin, mIL-3 (5 ng/mL) and olaparib (10  $\mu$ M) or DMSO for 24 h. Then, cells were washed twice with PBS and resuspended in 3 mL RPMI-1640 medium with 10% FCS, 1% penicillin/streptomycin and mIL-3 (5 ng/mL) and incubated for 4 h. Cells were centrifuged at  $400 \times g$  and the supernatant was isolated, sterile-filtered, and one half of the supernatant was added to  $5 \times 10^5$  32D *Jak2WT Brca1*<sup>+/+</sup> cells preincubated for 30 min with an IFN $\alpha$  receptor blocking antibody (10  $\mu$ g/mL). As a control group, the other half of the supernatant was added to  $5 \times 10^5$  32D *Jak2WT Brca1*<sup>+/+</sup> cells, and then, the cells were incubated for 24 h. Afterwards, RNA was isolated with the RNA purification kit from Macherey-Nagel (Düren, Germany) to generate cDNA and perform qPCRs.

#### 4.10. Cell Culture

We acquired 32D cells from the DSMZ and cultured them in RPMI-1640 medium with 10% WEHI-3B supernatant as mIL-3 source, 10% fetal calf serum, and 1% penicillin/streptomycin. Cells were cultured at 37 °C with 5% CO<sub>2</sub>. For the assays, to have a steady mIL-3 concentration, the RPMI-1640 medium was supplemented with 5 ng/mL mIL-3 instead of 10% WEHI-3B supernatant.

#### 4.11. Statistical Analysis

Statistical analysis was performed using GraphPad Prism 8.4.0 (GraphPad Software, Boston, MA, USA) to calculate independent *t*-tests or, in case of multiple comparisons and, unless otherwise stated, two-way ANOVAs (Tukey post hoc test). The results are displayed as individual values with mean and standard deviation (SD) if not indicated otherwise.

### 5. Conclusions

In summary, our study has demonstrated that *Brca1* haploinsufficiency induces DNA damage in *Jak2V617F*-positive cells while priming the type I interferon system via STING, rendering them more susceptible to olaparib treatment, whether applied as a standalone therapy or in conjunction with IFN $\alpha$ . This combined therapeutic approach, which targets DSB repair mechanisms, presents the potential for the treatment of MPN patients with germline DSB repair gene mutations, including those with familial and sporadic MPN. Further investigations are needed to fully elucidate the clinical implications of our findings and to assess the feasibility of implementing genetic counseling for DSB repair germline mutational testing in all MPN patients [7].

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms242417560/s1>.

**Author Contributions:** Conceptualization, M.B., S.K. and J.B.; Formal analysis, M.B., M.J.R., M.A.S.d.T., S.E., G.M.-N., T.H.B., N.C., S.K. and J.B.; Funding acquisition, S.K.; Investigation, M.B., M.J.R., M.A.S.d.T., S.E., G.M.-N., T.H.B., N.C., S.K. and J.B.; Methodology, M.B., M.J.R., S.E., G.M.-N. and J.B.; Supervision, S.K. and J.B.; Writing—original draft, M.B., M.J.R., T.H.B., S.K. and J.B.; Writing—review & editing, M.B., M.J.R., M.A.S.d.T., S.E., G.M.-N., T.H.B., N.C., S.K. and J.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported in part by funds from the German Cancer Aid (Deutsche Krebshilfe; DKH) to S.K. (70114726).

**Data Availability Statement:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments:** This work was in part supported by the Flow Cytometry Facility and the Confocal Microscopy Facility, core facilities of the Interdisciplinary Center for Clinical Research (IZKF) Aachen within the Faculty of Medicine at RWTH Aachen University. Parts of this work were generated within the MD thesis work of M.B. Illustrations were created with [Biorender.com](https://biorender.com) (license accessed on the 4 December 2023).

**Conflicts of Interest:** Steffen Koschmieder received research grant/funding from Geron, Janssen, AOP Pharma, and Novartis; received honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, PharmaEssentia, Sierra Oncology, Glaxo-Smith Kline (GSK), iOMEDICO, Abbvie, Astra Zeneca; received travel/accommodation support from Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, Sierra Oncology, GSK, iOMEDICO, and Karthos; had a patent issued for a BET inhibitor at RWTH Aachen University; participated on advisory boards for Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, Sierra Oncology, PharmaEssentia, AbbVie, Sierra Oncology, and GSK. Tim H Brümmendorf served as consultant/speaker for Gilead, Janssen, Merck, Novartis, Pfizer, and received research support from Novartis and Pfizer. The remaining authors do not declare any conflict of interest.

## References

- Vainchenker, W.; Kralovics, R. Genetic Basis and Molecular Pathophysiology of Classical Myeloproliferative Neoplasms. *Blood* **2017**, *129*, 667–679. [\[CrossRef\]](#) [\[PubMed\]](#)
- Brodmann, S.; Passweg, J.R.; Gratwohl, A.; Tichelli, A.; Skoda, R.C. Myeloproliferative Disorders: Complications, Survival and Causes of Death. *Ann. Hematol.* **2000**, *79*, 312–318. [\[CrossRef\]](#) [\[PubMed\]](#)
- Kreipe, H.; Hussein, K.; Göhring, G.; Schlegelberger, B. Progression of Myeloproliferative Neoplasms to Myelofibrosis and Acute Leukaemia. *J. Hematop.* **2011**, *4*, 61–68. [\[CrossRef\]](#)
- Deeg, H.J. Role of HSCT in Patients with MPD. *Hematol. Oncol. Clin. N. Am.* **2014**, *18*, 1023–1035. [\[CrossRef\]](#)
- Rumi, E.; Passamonti, F.; Della Porta, M.G.; Elena, C.; Arcaini, L.; Vanelli, L.; Del Curto, C.; Pietra, D.; Boveri, E.; Pascutto, C.; et al. Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. *J. Clin. Oncol.* **2007**, *25*, 5630–5635. [\[CrossRef\]](#) [\[PubMed\]](#)
- Rumi, E.; Cazzola, M. Diagnosis, Risk Stratification, and Response Evaluation in Classical Myeloproliferative Neoplasms. *Blood* **2017**, *129*, 680–692. [\[CrossRef\]](#)
- Elbracht, M.; Meyer, R.; Kricheldorf, K.; Gezer, D.; Eggermann, T.; Betz, B.; Kurth, I.; Teichmann, L.L.; Brümmendorf, T.H.; Germing, U.; et al. Germline Variants in DNA Repair Genes, Including BRCA1/2, May Cause Familial Myeloproliferative Neoplasms. *Blood Adv.* **2021**, *5*, 3373–3376. [\[CrossRef\]](#)
- Farmer, H.; McCabe, H.; Lord, C.J.; Tutt, A.H.J.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. *Nature* **2005**, *434*, 917–921. [\[CrossRef\]](#)
- Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase. *Nature* **2005**, *434*, 913–917. [\[CrossRef\]](#)
- Bridges, C.B. The Origin of Variations in Sexual and Sex-Limited Characters. *Am. Nat.* **1922**, *56*, 51–63. [\[CrossRef\]](#)
- Hartwell, L.H.; Szankasi, P.; Roberts, C.J.; Murray, A.W.; Friend, S.H. Integrating Genetic Approaches into the Discovery of Anticancer Drugs. *Science* **1997**, *278*, 1064–1068. [\[CrossRef\]](#) [\[PubMed\]](#)
- Buchholz, T.A.; Wu, X.; Hussain, A.; Tucker, S.L.; Mills, G.B.; Haffty, B.; Bergh, S.; Story, M.; Geara, F.B.; Brock, W.A. Evidence of Haplotype Insufficiency in Human Cells Containing a Germline Mutation in BRCA1 or BRCA2. *Int. J. Cancer* **2002**, *97*, 557–561. [\[CrossRef\]](#) [\[PubMed\]](#)
- Konishi, H.; Mohseni, M.; Tamaki, A.; Garay, J.P.; Croessmann, S.; Karnan, S.; Ota, A.; Wong, H.Y.; Konishi, Y.; Karakas, B.; et al. Mutation of a Single Allele of the Cancer Susceptibility Gene BRCA1 Leads to Genomic Instability in Human Breast Epithelial Cells. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 17773–17778. [\[CrossRef\]](#) [\[PubMed\]](#)
- Chen, E.; Sook Ahn, J.; Massie, C.E.; Clynes, D.; Godfrey, A.L.; Li, J.; Park, H.J.; Nangalia, J.; Silber, Y.; Mullally, A.; et al. JAK2V617F Promotes Replication Fork Stalling with Disease-Restricted Impairment of the Intra-S Checkpoint Response. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 15190–15195. [\[CrossRef\]](#) [\[PubMed\]](#)
- Marty, C.; Lacout, C.; Droin, N.; Le Couédic, J.P.; Ribrag, V.; Solary, E.; Vainchenker, W.; Villeval, J.L.; Plo, I. A Role for Reactive Oxygen Species in JAK2 V617F Myeloproliferative Neoplasm Progression. *Leukemia* **2013**, *27*, 2187–2195. [\[CrossRef\]](#) [\[PubMed\]](#)
- Li, J.; Spensberger, D.; Ahn, J.S.; Anand, S.; Beer, P.A.; Ghevaert, C.; Chen, E.; Forrai, A.; Scott, L.M.; Ferreira, R.; et al. JAK2 V617F Impairs Hematopoietic Stem Cell Function in a Conditional Knock-in Mouse Model of JAK2 V617F-Positive Essential Thrombocythemia. *Blood* **2010**, *116*, 1528–1538. [\[CrossRef\]](#) [\[PubMed\]](#)
- Plo, I.; Nakatake, M.; Malivert, L.; De Villartay, J.P.; Giraudier, S.; Villeval, J.L.; Wiesmuller, L.; Vainchenker, W. JAK2 Stimulates Homologous Recombination and Genetic Instability: Potential Implication in the Heterogeneity of Myeloproliferative Disorders. *Blood* **2008**, *112*, 1402–1412. [\[CrossRef\]](#) [\[PubMed\]](#)
- Härtlova, A.; Erttmann, S.F.; Raffi, F.A.M.; Schmalz, A.M.; Resch, U.; Anugula, S.; Lienenklaus, S.; Nilsson, L.M.; Kröger, A.; Nilsson, J.A.; et al. DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity. *Immunity* **2015**, *42*, 332–343. [\[CrossRef\]](#)
- Quintás-Cardama, A.; Kantarjian, H.; Manshouri, T.; Luthra, R.; Estrov, Z.; Pierce, S.; Richie, M.A.; Borthakur, G.; Konopleva, M.; Cortes, J.; et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients with Advanced Essential Thrombocythemia and Polycythemia Vera. *J. Clin. Oncol.* **2009**, *27*, 5418–5424. [\[CrossRef\]](#)

20. Mullally, A.; Bruedigam, C.; Poveromo, L.; Heidel, F.H.; Purdon, A.; Vu, T.; Austin, R.; Heckl, D.; Breyfogle, L.J.; Kuhn, C.P.; et al. Depletion of Jak2V617F Myeloproliferative Neoplasm-Propagating Stem Cells by Interferon- $\alpha$  in a Murine Model of Polycythemia Vera. *Blood* **2013**, *121*, 3692–3702. [[CrossRef](#)]
21. Austin, R.J.; Straube, J.; Bruedigam, C.; Pali, G.; Jacquelin, S.; Vu, T.; Green, J.; Gräsel, J.; Lansink, L.; Cooper, L.; et al. Distinct Effects of Ruxolitinib and Interferon-Alpha on Murine JAK2V617F Myeloproliferative Neoplasm Hematopoietic Stem Cell Populations. *Leukemia* **2020**, *34*, 1075–1089. [[CrossRef](#)] [[PubMed](#)]
22. Poh, W.; Dilley, R.L.; Moliterno, A.R.; Maciejewski, J.P.; Pratz, K.W.; McDevitt, M.A.; Herman, J.G. BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated MiR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies. *Clin. Cancer Res.* **2019**, *25*, 2513–2522. [[CrossRef](#)] [[PubMed](#)]
23. Sun, L.; Wu, J.; Du, F.; Chen, X.; Chen, Z.J. Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway. *Science* **2013**, *339*, 786–791. [[CrossRef](#)] [[PubMed](#)]
24. Maxwell, K.N.; Domchek, S.M.; Nathanson, K.L.; Robson, M.E. Population Frequency of Germline BRCA1/2 Mutations. *J. Clin. Oncol.* **2016**, *34*, 4183–4185. [[CrossRef](#)] [[PubMed](#)]
25. Hasselbalch, H.C. A New Era for IFN- $\alpha$  in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. *Expert Rev. Hematol.* **2011**, *4*, 637–655. [[CrossRef](#)] [[PubMed](#)]
26. Essers, M.A.G.; Offner, S.; Blanco-Bose, W.E.; Waibler, Z.; Kalinke, U.; Duchosal, M.A.; Trumpp, A. IFN $\alpha$  Activates Dormant Haematopoietic Stem Cells in Vivo. *Nature* **2009**, *458*, 904–908. [[CrossRef](#)] [[PubMed](#)]
27. Kirschner, M.; Bornemann, A.; Schubert, C.; Gezer, D.; Kricheldorf, K.; Isfort, S.; Brümmendorf, T.H.; Schemionek, M.; Chatain, N.; Skorski, T.; et al. Transcriptional Alteration of DNA Repair Genes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. *Ann. Hematol.* **2019**, *98*, 2703–2709. [[CrossRef](#)]
28. Nieborowska-Skorska, M.; Maifrede, S.; Dasgupta, Y.; Sullivan, K.; Flis, S.; Le, B.V.; Solecka, M.; Belyaeva, E.A.; Kubovcakova, L.; Nawrocki, M.; et al. Ruxolitinib-Induced Defects in DNA Repair Cause Sensitivity to PARP Inhibitors in Myeloproliferative Neoplasms. *Blood* **2017**, *130*, 2848–2859. [[CrossRef](#)]
29. Corrales, L.; McWhirter, S.M.; Dubensky, T.W.; Gajewski, T.F. The Host STING Pathway at the Interface of Cancer and Immunity. *J. Clin. Investig.* **2016**, *126*, 2404–2411. [[CrossRef](#)]
30. Pantelidou, C.; Sonzogni, O.; Taveira, M.D.O.; Mehta, A.K.; Kothari, A.; Wang, D.; Visal, T.; Li, M.K.; Pinto, J.; Castrillon, J.A.; et al. Parp Inhibitor Efficacy Depends on CD8<sup>+</sup> T-Cell Recruitment via Intratumoral Sting Pathway Activation in Brca-Deficient Models of Triple-Negative Breast Cancer. *Cancer Discov.* **2019**, *9*, 722–737. [[CrossRef](#)]
31. Nambiar, D.K.; Mishra, D.; Singh, R.P. Targeting DNA Repair for Cancer Treatment: Lessons from PARP Inhibitor Trials. *Oncol. Res.* **2023**, *31*, 405–421. [[CrossRef](#)] [[PubMed](#)]
32. Guo, X.X.; Wu, H.L.; Shi, H.Y.; Su, L.; Zhang, X. The Efficacy and Safety of Olaparib in the Treatment of Cancers: A Meta-Analysis of Randomized Controlled Trials. *Cancer Manag. Res.* **2018**, *10*, 2553–2562. [[CrossRef](#)] [[PubMed](#)]
33. McMahon, M.; Frangova, T.G.; Henderson, C.J.; Wolf, C.R. Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New P21 Reporter Mouse. *Mol. Cancer Res.* **2016**, *14*, 1195–1203. [[CrossRef](#)] [[PubMed](#)]
34. Zhao, Q.; Ma, P.; Fu, P.; Wang, J.; Wang, K.; Chen, L.; Yang, Y. Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. *Front. Pharmacol.* **2022**, *13*, 912256. [[CrossRef](#)]
35. Baumeister, J.; Chatain, N.; Hubrich, A.; Maié, T.; Costa, I.G.; Denecke, B.; Han, L.; Küstermann, C.; Sontag, S.; Seré, K.; et al. Hypoxia-Inducible Factor 1 (HIF-1) Is a New Therapeutic Target in JAK2V617F-Positive Myeloproliferative Neoplasms. *Leukemia* **2020**, *34*, 1062–1074. [[CrossRef](#)]
36. Han, L.; Schubert, C.; Köhler, J.; Schemionek, M.; Isfort, S.; Brümmendorf, T.H.; Koschmieder, S.; Chatain, N. Calreticulin-Mutant Proteins Induce Megakaryocytic Signaling to Transform Hematopoietic Cells and Undergo Accelerated Degradation and Golgi-Mediated Secretion. *J. Hematol. Oncol.* **2016**, *9*, 45. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.